This Week in Nature

A news story in Nature this week reports on the FANTOM consortium, which used high-throughput sequencing to create a timeline of mRNA produced by human leukemia cells in response to the presence of phorbol myristate acetate. They used RNAi across 52 transcription factors to verify the identity of key transcription regulators, their time-dependent activities, and target genes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.

Aug
15
Sponsored by
Swift Biosciences

This webinar will discuss the Cancer Avatar Project at the California Pacific Medical Center Research Institute (CPMCRI) and the efforts to overcome complexity of tumor profiling using the Accel-Amplicon sequencing workflow from Swift Biosciences.

Aug
27
Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sep
12
Sponsored by
Qiagen

This webinar will discuss ongoing work to apply T-cell receptor sequencing (TCRseq) approaches to immunotherapy monitoring for melanoma patients.